Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
GLAUKOS Corporation has 10 pending office actions in Medical Devices & Mechanical Engineering. The portfolio involves 10 examiners across 8 art units, showing broad examiner distribution and some concentration of matters within shared technical examination groups.
WIEST, PHILIP R is the busiest examiner, with 1 pending matter. No examiner accounts for more than that figure, so the docket requires coordination across many individual examination relationships rather than reliance on one examiner strategy.
The art-unit structure provides a basis for identifying recurring technical issues, while the examiner spread calls for tailored prosecution responses. Portfolio oversight should connect related matters without assuming that a position accepted in one file will transfer unchanged to another.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (50%) |
| §112 only | 1 (10%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WIEST, PHILIP R | 1 | 81.5% | +16.1% |
| LEVY, BRANDON WILLIAM | 1 | 62.9% | +46.5% |
| FARRAR, LAUREN PENG | 1 | 78.7% | +15.6% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| PELTON, NATHANIEL R | 1 | 74.5% | +18.9% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| DARB, HAMZA A. | 1 | 74.5% | +31.1% |
| TOTH, KAREN E | 1 | 46.4% | +25.8% |
| MANNAN, MIKAIL A | 1 | 68.3% | +24.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18965923 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | WIEST, PHILIP R | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18540296 | INTRAOCULAR PHYSIOLOGICAL SENSOR | PELTON, NATHANIEL R | — |
| 18319380 | APPLICATIONS OF ZWITTERIONS IN OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND PREPARATIONS | ROBINSON, MIKHAIL O'DONNEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18310109 | DRUG-ELUTING OCULAR IMPLANT | DARB, HAMZA A. | 36d |
| 18965923 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | WIEST, PHILIP R | — |
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | LEVY, BRANDON WILLIAM | — |
| 18641263 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME | FARRAR, LAUREN PENG | — |
| 18606217 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | VALLE, ERNESTO | — |
| 18540296 | INTRAOCULAR PHYSIOLOGICAL SENSOR | PELTON, NATHANIEL R | — |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | BASQUILL, SEAN M | — |
| 18319380 | APPLICATIONS OF ZWITTERIONS IN OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND PREPARATIONS | ROBINSON, MIKHAIL O'DONNEL | — |
| Art Unit | Apps |
|---|---|
| 3781 | 2 |
| 3783 | 2 |
| 1623 | 1 |
| 2859 | 1 |
| 1614 | 1 |
| 1627 | 1 |
| 3791 | 1 |
| 3774 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18965923 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | WIEST, PHILIP R | 3781 | DP | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18913142 | INSERTION SYSTEM FOR DELIVERY OF ACTIVE PHARMACEUTICAL AGENTS INSIDE THE EYE | LEVY, BRANDON WILLIAM | 3781 | §103 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18641263 | IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME | FARRAR, LAUREN PENG | 3783 | §102§103DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18606217 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | VALLE, ERNESTO | 1623 | §103 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18540296 | INTRAOCULAR PHYSIOLOGICAL SENSOR | PELTON, NATHANIEL R | 2859 | §102§103 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18359642 | OPHTHALMIC TOPICAL CREAM FORMULATIONS AND USES THEREOF | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Jul 26, 2023 |
| 18319380 | APPLICATIONS OF ZWITTERIONS IN OPHTHALMIC TOPICAL CREAM COMPOSITIONS AND PREPARATIONS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§103 | Non-Final OA | — | Pending | May 17, 2023 |
| 18310109 | DRUG-ELUTING OCULAR IMPLANT | DARB, HAMZA A. | 3783 | §103 | Non-Final OA | 36d | Pending | May 01, 2023 |
| 17844497 | INTRAOCULAR PHYSIOLOGICAL SENSOR | TOTH, KAREN E | 3791 | §112 | Final Rejection | — | Pending | Jun 20, 2022 |
| 17125466 | OCULAR TISSUE PERFORATION DEVICE | MANNAN, MIKAIL A | 3774 | §103 | Final Rejection | — | Pending | Dec 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGLAUKOS Corporation has 10 pending office actions as of October 2026, spread across 8 art units and 10 examiners.
Philip R Wiest has the most, with 1 of GLAUKOS Corporation's pending office actions.
Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.
